HK1081445A1 - Materials and methods for preventing and treating microbe-mediated epithelial disorders - Google Patents

Materials and methods for preventing and treating microbe-mediated epithelial disorders

Info

Publication number
HK1081445A1
HK1081445A1 HK06101710.1A HK06101710A HK1081445A1 HK 1081445 A1 HK1081445 A1 HK 1081445A1 HK 06101710 A HK06101710 A HK 06101710A HK 1081445 A1 HK1081445 A1 HK 1081445A1
Authority
HK
Hong Kong
Prior art keywords
methods
polyethylene glycol
preventing
gut
molecular weight
Prior art date
Application number
HK06101710.1A
Other languages
English (en)
Inventor
John Cd Alverdy
Original Assignee
Univ Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chicago filed Critical Univ Chicago
Publication of HK1081445A1 publication Critical patent/HK1081445A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/105—Aliphatic or alicyclic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Birds (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pediatric Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
HK06101710.1A 2002-11-26 2006-02-09 Materials and methods for preventing and treating microbe-mediated epithelial disorders HK1081445A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/037948 WO2004047778A1 (en) 2002-11-26 2002-11-26 Materials and methods for preventing and treating microbe-mediated epithelial disorders

Publications (1)

Publication Number Publication Date
HK1081445A1 true HK1081445A1 (en) 2006-05-19

Family

ID=32391449

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06101710.1A HK1081445A1 (en) 2002-11-26 2006-02-09 Materials and methods for preventing and treating microbe-mediated epithelial disorders

Country Status (14)

Country Link
US (3) US20060198817A1 (ja)
EP (1) EP1567117B1 (ja)
JP (1) JP5271475B2 (ja)
KR (1) KR101087412B1 (ja)
CN (1) CN100536836C (ja)
AT (1) ATE544354T1 (ja)
AU (1) AU2002352938B8 (ja)
BR (1) BR0215954A (ja)
CA (1) CA2507018C (ja)
DK (1) DK1567117T3 (ja)
ES (1) ES2381998T3 (ja)
HK (1) HK1081445A1 (ja)
PT (1) PT1567117E (ja)
WO (1) WO2004047778A1 (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0510004A (pt) * 2004-04-20 2007-09-18 Univ Chicago artigo de manufatura, métodos para administrar uma composição terapêutica a um epitélio de um indivìduo, para tratar uma condição mediada por micróbio de um epitélio de um indivìduo, para melhorar um sintoma de uma condição e para prevenir uma condição, e, uso de composto tipo peg pma
GB2421908A (en) * 2004-12-23 2006-07-12 Univ College London Hospitals Medicament for treatment of inflammatory diseases
EP1906838A4 (en) * 2005-06-03 2008-10-08 Univ Chicago INTERACTION MODULATION OF MICROBIAL PATHOGENS-HOST CELLS
US20090186949A1 (en) * 2006-02-28 2009-07-23 The University Of Chicago Method for Treating Endothelial and Epithelial Cell Disorders by Administering High Molecular Weight PEG-Like Compounds
GB0612748D0 (en) * 2006-06-27 2006-08-09 Univ College London Hospitals Treatment and/or prevention of inflammatory lung disease
WO2009036081A1 (en) * 2007-09-10 2009-03-19 University Of Kentucky Research Foundation Systems and methods for diagnosis and monitoring of bacteria-related conditions
US20120078017A1 (en) * 2009-03-23 2012-03-29 Alverdy John C Methods for preventing and treating radiation-induced epithelial disorders
US9504736B2 (en) 2010-09-23 2016-11-29 The Regents Of The University Of California Administration of serine protease inhibitors to the stomach
SG191394A1 (en) 2010-12-31 2013-08-30 Abbott Lab Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
SG10202110501RA (en) 2010-12-31 2021-11-29 Abbott Lab Methods For Decreasing The Incidence Of Necrotizing Enterocolitis In Infants, Toddlers, Or Children Using Human Milk Oligosaccharides
US20140057993A1 (en) * 2011-04-27 2014-02-27 Northshore University Healthsystem Prophylaxis and Treatment of Enteropathogenic Bacterial Infection
MY182335A (en) 2011-07-22 2021-01-19 Abbott Lab Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
CN104023560A (zh) 2011-08-29 2014-09-03 雅培制药有限公司 用于预防胃肠道损伤和/或促进胃肠道愈合的人乳寡糖
AU2012307157B2 (en) * 2011-09-16 2017-08-03 Ucb Pharma S.A. Neutralising antibodies to the major exotoxins TcdA and TcdB of Clostridium difficile
CN103520202B (zh) * 2012-07-02 2015-09-02 舒泰神（北京）生物制药股份有限公司 用于通便和清肠的药物组合物
ES2744828T3 (es) * 2013-03-15 2020-02-26 Midway Pharmaceuticals Inc Gestión de la osteoporosis con PEG APM
ITPD20130133A1 (it) * 2013-05-14 2014-11-15 Sanypet S P A Prodotto per l'alimentazione di cani affetti da disturbi infiammatori dell'intestino
AU2015236283B2 (en) 2014-03-25 2020-05-07 Leading BioSciences, Inc. Compositions for the treatment of autodigestion
WO2018064536A1 (en) 2016-09-30 2018-04-05 The University Of Chicago Phosphorylated tri-block copolymers with pathogen virulence-suppressing properties
CN109637293B (zh) * 2019-02-16 2020-11-24 哈尔滨学院 一种用于蒲丰投针实验的数学概率演示装置
EP3791885A1 (en) * 2019-09-13 2021-03-17 Consejo Superior de Investigaciones Cientificas (CSIC) Polyethylene glycol for use in the prevention of abdominal inflammatory diseases and/or associated diseases
CN115531364B (zh) * 2021-06-30 2024-02-23 中国科学技术大学 预防或治疗轮状病毒感染的微生物代谢物制剂及其用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3487150A (en) * 1965-10-23 1969-12-30 Cornell Res Foundation Inc Dextran sulphate treatment of peptic ulcers
NL154598B (nl) * 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) * 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) * 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) * 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) * 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4837008A (en) * 1985-04-09 1989-06-06 Peroxydent Group Periodontal composition and method
US4659572A (en) * 1985-04-15 1987-04-21 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Burn wound dressing material
USH1198H (en) * 1985-04-26 1993-06-01 Cetus Corporation Pseudomonas aeruginosa type-specific human monoclonal antibodies, their preparation and use
NZ218499A (en) * 1985-12-10 1990-04-26 Genetic Systems Corp Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods
US4977137B1 (en) * 1987-06-03 1994-06-28 Baylor College Medicine Lactoferrin as a dietary ingredient promoting the growth of the gastrointestinal tract
US5661177A (en) * 1988-11-09 1997-08-26 Chimie Et Biologie Zinc cysteate its preparation and uses in pharmacy and cosmetology
SE465109B (sv) 1989-10-30 1991-07-29 Bengt Andersson Antibakteriell komposition
US5169627A (en) * 1991-10-28 1992-12-08 Mount Sinai School Of Medicine Of The City University Of New York Oral pharmaceutical composition containing a polyethylene glycol-immunoglobulin G conjugate for reconstitution of secretory immunity and method of reconstituting secretory immunity
US5409903A (en) * 1992-02-18 1995-04-25 Urecap Corporation Method and compositions for the treatment of H. pylori and dermatitis
US5350770A (en) * 1992-07-28 1994-09-27 Elford Howard L Therapeutic process for the treatment of septic shock
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
US6074671A (en) * 1993-10-01 2000-06-13 Legere Pharmaceuticals, Ltd. Method of using lectins for contraception and prophylaxis against diseases transmittable by sexual contact and condom containing lectins
US6126933A (en) * 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US6017334A (en) 1996-10-03 2000-01-25 Board Of Regents, The University Of Texas System Modified surfaces resistant to bacterial colonization
US6321909B1 (en) * 1997-02-13 2001-11-27 Sky High, Llc System for storing polyethylene glycol solutions
ES2317666T3 (es) * 1997-06-03 2009-04-16 Ganeden Biotech, Inc. Bacteria acida lactica probiotica para tratar infecciones bacterianas asociadas con el sids.
CA2301921A1 (en) * 1997-08-20 1999-02-25 John Graham Goddard Compositions containing polyethylene glycol and uses thereof
MY138335A (en) * 1997-09-15 2009-05-29 Procter & Gamble Antimicrobial quinolones, their compositions and uses
DE69909747T2 (de) * 1998-02-09 2004-04-15 Enzon Pharmaceuticals, Inc. Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen
ATE378067T1 (de) 1999-08-18 2007-11-15 Industy Academic Cooperation F Agent zur induktion einer immunologischen toleranz
AU7367000A (en) 1999-09-10 2001-04-10 Children's Medical Center Corporation Method for treating and preventing bacterial infection
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
CN1491676A (zh) 2002-10-22 2004-04-28 刘小兵 经皮式(或口服式)避孕堕胎杀菌组合物

Also Published As

Publication number Publication date
AU2002352938B2 (en) 2009-09-10
CA2507018C (en) 2014-03-25
US20060198817A1 (en) 2006-09-07
EP1567117B1 (en) 2012-02-08
EP1567117A1 (en) 2005-08-31
PT1567117E (pt) 2012-05-09
JP5271475B2 (ja) 2013-08-21
ATE544354T1 (de) 2012-02-15
US9549946B2 (en) 2017-01-24
AU2002352938B8 (en) 2009-10-08
KR20050115855A (ko) 2005-12-08
JP2006515837A (ja) 2006-06-08
DK1567117T3 (da) 2012-05-21
AU2002352938A1 (en) 2004-06-18
CN1697644A (zh) 2005-11-16
US20160129038A1 (en) 2016-05-12
EP1567117A4 (en) 2009-07-08
BR0215954A (pt) 2005-09-13
CA2507018A1 (en) 2004-06-10
WO2004047778A1 (en) 2004-06-10
US20170281668A1 (en) 2017-10-05
KR101087412B1 (ko) 2011-11-25
ES2381998T3 (es) 2012-06-04
CN100536836C (zh) 2009-09-09

Similar Documents

Publication Publication Date Title
HK1081445A1 (en) Materials and methods for preventing and treating microbe-mediated epithelial disorders
WO2006073430A3 (en) Therapeutic delivery system comprising a high molecular weight peg-like compound
EP1496076A4 (en) HYDROPHILIC Y-BRANCH POLYMER DERIVATIVE AND METHOD OF MANUFACTURING THEREOF; ABOVE CONNECTED MEDICAL COMPOSITE
IL225192A (en) Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
EP2322219A3 (en) Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
NZ588913A (en) Liver cancer drug
DK1543063T3 (da) Medikament levering
HK1135923A1 (en) Pharmaceutical agent having long-lasting effect of treating arthritic disorders
AR074196A1 (es) Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
EP2358395A4 (en) METHOD AND FORMULATION FOR REDUCING THE AGGREGATION OF A MACROMOLECULUM UNDER PHYSIOLOGICAL CONDITIONS
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
WO2011081493A3 (en) Pharmaceutical composition comprising metformin and rosuvastatin
WO2009037583A3 (en) Compositions and methods for treatment and prevention of osteoarthritis
JP2017043639A (ja) 疼痛抑制用医薬組成物
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
HK1098352A1 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
JP2016512247A5 (ja)
MY153932A (en) A medicinal product and treatment
BR112015011294A8 (pt) nanopartículas com polímero biodegradável e biocompatível plga carregadas com o fármaco pentoxifilina de uso humano e uso destas
JP2009522218A5 (ja)
WO2006089120A3 (en) Compositions, methods of use and preparation of 2,6-diisopropyl phenol and analogs for ischemic injury
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.
RS20060435A (en) Compostions comprising glycosaminoglycan and nonsteroidal anti-inflammatory drug
Scahill et al. " Risperidone in children with autism and serious behavioral problems": Reply.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20201126